SCHEMBL4831334

SCHEMBL4831334

O=C(c1cccc(N2CCOCC2)c1)N1CCOCC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.72
MEN1 O00255 1/20 0.65
KMT2A Q03164 1/20 0.65
TSHR P16473 4/20 0.65
LMNA P02545 2/20 0.65
MAPK1 P28482 2/20 0.65
USP2 O75604 1/20 0.65
MAPT P10636 1/20 0.65
PLOD2 O00469 1/20 0.61
PLOD3 O60568 1/20 0.61
PLOD1 Q02809 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
KDM4E B2RXH2 3/20 0.59
HPGD P15428 2/20 0.59
MGLL Q99685 1/20 0.58
RECQL P46063 1/20 0.58
AKR1C3 P42330 1/20 0.57
L3MBTL3 Q96JM7 1/20 0.57
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10720509 0.87 L3MBTL1 (0.71) MEN1KMT2ATSHRLMNAMAPK1
SCHEMBL303084 0.84 KMO (0.77) KMOMEN1KMT2ATSHRLMNA
SCHEMBL65857 0.84 KMO (1.00) KMOMEN1KMT2ATSHRLMNA
SCHEMBL30634127 0.84 KMO (1.00) KMOMEN1KMT2ATSHRLMNA
SCHEMBL30568869 0.83 L3MBTL1 (0.62) MEN1KMT2ATSHRL3MBTL1KDM4E
SCHEMBL3227656 0.83 MEN1 (0.63) MEN1KMT2ATSHRLMNAMAPK1
SCHEMBL520393 0.83 L3MBTL1 (0.62) MEN1KMT2ATSHRL3MBTL1KDM4E
SCHEMBL4251811 0.83 KMO (0.74) KMOMEN1KMT2ATSHRLMNA
SCHEMBL13724478 0.83 KMO (0.74) KMOMEN1KMT2ATSHRLMNA
Hydrochloric Acid SCHEMBL14742166 0.83 KMO (0.74) KMOMEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442704-B2 Amide derivatives ASTRAZENECA AB (SE) 2008-10-28 US disclosed
CN-100415724-C Pyrimidine derivatives ASTRAZENECA AB (SE) 2008-09-03 CN disclosed
US-7332483-B2 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease ASTRAZENECA AB (SE) 2008-02-19 US disclosed
US-20060281734-A1 Amide derivatives BROWN DEARG S 2006-12-14 US disclosed
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
US-7008945-B1 Amide derivatives ASTRAZENECA AB (SE) 2006-03-07 US disclosed
US-20050245551-A1 Amide derivatives ASTRAZENECA AB 2005-11-03 US disclosed
US-6956037-B2 Benzamide derivatives for the treatment of diseases mediated by cytokines ASTRAZENECA AB (SE) 2005-10-18 US disclosed
CN-1188389-C Benzamide derivatives for the treatment of diseases mediated by cytokines ASTRA ZENECA LTD (SE) 2005-02-09 CN disclosed
US-6846827-B1 Pyrimidine derivatives ASTRAZENECA AB (SE) 2005-01-25 US disclosed
EP-1077930-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES AstraZeneca AB (SE) 2001-02-28 EP disclosed
EP-1077931-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES AstraZeneca AB (SE) 2001-02-28 EP disclosed
WO-2000055153-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2000-09-21 WO disclosed
EP-1017378-A1 AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES AstraZeneca UK Limited (GB) 2000-07-12 EP disclosed
WO-2000020402-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2000-04-13 WO disclosed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 WO disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed
WO-1999059960-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ASTRAZENECA AB (SE) 1999-11-25 WO disclosed
WO-1999059959-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ASTRAZENECA AB (SE) 1999-11-25 WO disclosed
WO-1999015164-A1 AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ZENECA LIMITED (GB) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245551-A1 Amide derivatives IL6, IL6ST, IL1B KMO 241/4885MEN1 2386/4885KMT2A 2740/4885
US-20060281734-A1 Amide derivatives IL6, IL6ST, IL1B KMO 241/4885MEN1 2386/4885KMT2A 2740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.